1. Nixon JE. Avascular necrosis of bone: a review. J R Soc Med. 1983; 76(8): 681-92.

2. Mirzai R, Chang C, Greenspan A, Gershwin ME. Avascular necrosis. Compr Ther. 1998; 24(5): 251-5.

3. Kerachian MA, Harvey EJ, Cournoyer D, Chow TY, Seguin C. Avascular necrosis of the femoral head:vascular hypotheses. Endothelium. 2006; 13(4):237-44.

4. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 2009; 140(7):864-75.

5. Marx RE, Tursun R. Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg. 2012;41(3): 283-9.

6. Wimalawansa SJ. Insight into bisphosphonateassociated osteomyelitis of the jaw:pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008; 7(4):491-512.

7. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008; 3 Suppl 3: S131-9.

8. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010;11(4): 219-27.

9. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19(1): 80-100.

10. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 2008; 14(3): 277-85.

11. Kidd LJ, Cowling NR, Wu AC, Kelly WL, Forwood MR. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res. 2011; 29(12): 1827-33.

12. Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonateassociated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009; 45(5): 843-52.

13. AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3): 369-76.

14. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and nonresorbing cells. Bone. 2008; 42(5): 848-60.

15. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009; 44(1): 4-10.

16. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011; 1218: 62-79.

17. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009; 122(2 Suppl): S33-45.

18. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw:so many hypotheses, so few data. J Oral Maxillofac Surg. 2009; 67(5 Suppl): 61-70.

19. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosteronestimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62(22): 6538-44.

20. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302(3): 1055-61.

21. Guise TA. Antitumor effects of bisphosphonates:promising preclinical evidence. Cancer Treat Rev. 2008; 34 Suppl 1: S19-24.

22. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg. 2003;61(9): 1115-7.

23. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22): 4253-4.

24. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010; 122(1): 181-8.

25. Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. Clin Cancer Res. 2011; 17(6): 1405-14.

26. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006; 35(3): 155-60.

27. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012; 12(3 Suppl): 233-47.

28. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66(5): 987-94.

29. Allen MR. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009; 189(1-4): 289-94.

30. Paparella ML, Brandizzi D, Santini-Araujo E, Cabrini RL. Histopathological features of osteonecrosis of the jaw associated with bisphosphonates. Histopathology. 2012; 60(3):514-6.

31. Allen MR. The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology. 2011; 99(1): 8-17.

32. Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in nearcomplete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res. 2010; 25(1): 98-105.

33. Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg. 2010; 68(5): 1158-61.

34. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67(7): 1363-72.

35. Choi SY, An CH, Kim SY, Kwon TG. Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients. . J Oral &Maxillofac Surg Med Pathol. 2013; 25: 123-8.

36. Kwon TG, Choi SY, Ahn BC, An CH. Comparison of chronic osteomyelitis versus bisphosphonaterelated osteonecrosis of the jaws in female patients without malignant bone disease Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2013; 25(3): 201-98.

37. Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone. 2013; 57(1): 201-5.

38. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc. 2009; 140(10): 1259-65.

39. Hansen T, Kirkpatrick CJ, Walter C, Kunkel M. Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonateassociated osteonecrosis--a paradoxical observation? Virchows Arch. 2006; 449(4): 448-54.

40. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010; 28(2): 165-75.

41. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 1996; 64(7): 2371-80.

42. Allam E, Allen M, Chu TM, Ghoneima A, Jack Windsor L. In vivo effects of zoledronic acid on oral mucosal epithelial cells. Oral Dis. 2011;17(3): 291-7.

43. Reddy GT, Kumar TM, Veena. Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv. 2005; 12(4): 217-22.

44. Kos M, Brusco D, Kuebler J, Engelke W. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration. Int J Oral Maxillofac Surg. 2010; 39(11): 1097-102.

45. Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res. 2011; 26(8): 1871-82.

46. Abtahi J, Agholme F, Sandberg O, Aspenberg P. Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. J Oral Pathol Med. 2012; 41(6):494-9.

47. Jones AC, Sedghizadeh PP. Bisphosphonaterelated osteonecrosis of the jaws is caused by dental procedures that violate oral epithelium;this is no longer a mysterious disease. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117(3):392-3.

48. Pichardo SE, van Merkesteyn JP. Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116(3): 287-92.

49. Aspenberg P. Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf. 2006;5(6): 743-5.

50. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg. 2011; 69(11):e364-71.

51. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphon ates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. J Craniomaxillofac Surg. 2011; 39(4): 272-7.

52. Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011; 47(3): 191-4.

53. Corrado A, Santoro N, Cantatore FP. Extraskeletal effects of bisphosphonates. Joint Bone Spine. 2007; 74(1): 32-8.

54. Oizumi T, Funayama H, Yamaguchi K, Yokoyama M, Takahashi H, Yamamoto M, et al. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. J Oral Maxillofac Surg. 2010; 68(5): 1043-54.

55. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39(4): 872-9.

56. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357(9): 905-16.

57. Brennan O, Kennedy OD, Lee TC, Rackard SM, O'Brien FJ. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res. 2011; 29(3): 419-24.

58. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw:a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig. 2010; 14(3): 271-84.

59. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011; 22(12): 2951-61.

60. Subramanian G, Fritton JC, Quek SY. Osteonecrosis and atypical fractures-common origins? Osteoporos Int. 2013; 24(2): 745-6.

61. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment. Lancet Oncol. 2006; 7(6): 508-14.

62. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonaterelated osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010; 28(4): 365-83.